SAN.PA Sanofi
Company Analysis
Latest News
Sanofi Halts Development of Eczema Drug Amlitelimab
Sanofi discontinued clinical development of amlitelimab for moderate-to-severe atopic dermatitis on Friday. The company will not seek global regulatory...
Sanofi Sues Pfizer and Moderna, Claiming Infringement of mRNA Delivery Patents
Sanofi filed patent infringement lawsuits against Pfizer and Moderna in New Jersey federal court. The French drugmaker claims their COVID-19 vaccines use...
Sanofi Wins FDA Approval for First Wearable Cancer Injector, Diversifying Revenue
Sanofi received FDA approval for Sarclisa Escena, a subcutaneous treatment for multiple myeloma. This marks the first anticancer therapy approved for...
Sanofi hit with FDA warning, citing adulterated drugs at Irish plant
The U.S. Food and Drug Administration (FDA) issued a warning letter to Sanofi’s Genzyme Ireland Limited facility in Waterford, Ireland. Inspectors identified...
Sanofi Nexviazyme hits goals in rare Pompe disease trial, eyes 2026 filing
Sanofi announced that its drug Nexviazyme met all primary and secondary goals in the Phase 3 Baby-COMET study. The trial treated infantile-onset Pompe disease...
Sanofi Taps Roche Veteran Paulo Fontoura to Lead Global R&D Transformation
Sanofi appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma. The appointment becomes effective September 1,...
Sanofi Wins EU Approval for Cenrifki, First to Target MS Disability
The European Commission approved Sanofi's drug Cenrifki (tolebrutinib) for adults with secondary progressive multiple sclerosis (SPMS) without recent relapses....
Sanofi Wins Japan Approval for Sarclisa Injection, Reducing Patient Treatment Burden
Sanofi received approval from Japan’s Ministry of Health, Labour and Welfare for the subcutaneous formulation of Sarclisa. This isatuximab injection treats...
Sanofi wins FDA approval for Tzield, first Stage 3 pediatric diabetes drug
Sanofi received FDA accelerated approval for Tzield (teplizumab-mzwv). The treatment targets children aged eight to 17 recently diagnosed with stage 3 type 1...
Sanofi Halts Phase 3 Riliprubart Trial, Citing Lack of Efficacy
Sanofi terminated its Phase 3 MOBILIZE clinical trial for riliprubart, an investigational antibody targeting chronic inflammatory demyelinating polyneuropathy...